Masimo Corporation (NASDAQ:MASI – Get Free Report) hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $179.00 and last traded at $178.9450, with a volume of 220634 shares changing hands. The stock had previously closed at $178.90.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on MASI. Wolfe Research cut Masimo from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. Wells Fargo & Company raised Masimo to a “hold” rating in a research report on Wednesday, March 18th. Stifel Nicolaus set a $180.00 price objective on Masimo in a research report on Tuesday, February 17th. BTIG Research cut Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Finally, Piper Sandler cut Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price objective for the company. in a research report on Tuesday, February 17th. Nine analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $180.40.
Read Our Latest Report on Masimo
Masimo Trading Down 0.0%
Institutional Trading of Masimo
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new stake in Masimo during the 4th quarter worth about $27,000. Aster Capital Management DIFC Ltd acquired a new stake in Masimo during the 4th quarter worth about $28,000. Los Angeles Capital Management LLC acquired a new stake in Masimo during the 4th quarter worth about $31,000. Western Wealth Management LLC acquired a new stake in Masimo during the 1st quarter worth about $44,000. Finally, Rothschild Investment LLC lifted its position in Masimo by 12,950.0% during the 4th quarter. Rothschild Investment LLC now owns 261 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 259 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.
Masimo Company Profile
Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.
In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.
Further Reading
- Five stocks we like better than Masimo
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.
